The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

May. 12, 2016
Applicant:

The United States of America, As Represented BY the Secretary,department of Health and Human Services, Bethesda, MD (US);

Inventors:

John A. Chiorini, Dayton, MD (US);

Giovanni Di Pasquale, Kensington, MD (US);

Randy Chandler, Chevy Chase, MD (US);

Charles P. Venditti, Potomac, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2020.01); C12N 15/86 (2006.01); C07K 14/635 (2006.01); C12N 9/90 (2006.01); A61P 5/14 (2006.01); C07K 14/48 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61P 5/14 (2018.01); C07K 14/48 (2013.01); C07K 14/635 (2013.01); C12N 9/90 (2013.01); C12Y 504/99002 (2013.01); C07K 2319/02 (2013.01); C12N 2750/14121 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition. The invention further provides a method of treating methylmalonic acidaemia (MMA) in a mammal comprising administering an AAV vector comprising a heterologous nucleic acid sequence encoding methylmalonyl CoA mutase enzyme to the mammal.


Find Patent Forward Citations

Loading…